Gilead Sciences stock reports growth at EUR 133.42, plus 0.02 percent

{
  "signal_id": "a07027d8-638c-2569-2167-86ccbdfd29e4",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-30T12:43:21+00:00",
  "company": {
    "name": "Gilead",
    "domain": "gilead.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/gilead-sciences-stock-reports-growth-at-eur-133-42-plus-0-02-percent/70204461",
    "title": "Gilead Sciences stock reports growth at EUR 133.42, plus 0.02 percent - AD HOC NEWS",
    "excerpt": "Gilead Sciences stock (ISIN US3755581036) was trading at EUR 133.42 at Lang & Schwarz on September 30, 2026 at 2:33 p.m. CEST, plus 0.02 percent versus the prior close of EUR 133.39. The company reported USD 7.80 billion in second-quarter 2026 revenue, up 10.6 percent year over year, while a September 30 report linked Gilead to a USD 2.5 million federal grant for oral treatments targeting mosquito-borne flaviviruses. MarketBeat reported that Gilead's second-quarter adjusted loss was USD 6.75 per share, narrower than the USD 7.25 consensus loss, while revenue reached USD 7.80 billion against USD 7.40 billion expected. The revenue comparison gives the quarterly result its clearest strength, even as the reported earnings figure remained negative. Zacks said second-quarter HIV product sales rose 12 percent to USD 5.69 billion, including USD 232 million from Yeztugo. The company raised its full-year HIV sales growth guidance to 9-10 percent from 8 percent and projected 2026 product sales of USD 30.10-30.40 billion. As Simply Wall St reported on September 30, 2026, Gilead secured a USD 2.5 million federal grant with research partners for oral flavivirus treatments. The development adds an infectious-disease research angle beyond the established HIV franchise, although its commercial value depends on research and regulatory progress. Gilead also expanded licensing arrangements for...",
    "product": "oral flavivirus treatments",
    "summary": "Gilead Sciences is developing oral treatments for mosquito-borne flaviviruses, supported by a new federal grant.",
    "planning": true,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2699361_1920_1080.webp",
    "confidence": 0.9,
    "product_data": {
      "name": "oral flavivirus treatments",
      "full_text": "oral flavivirus treatments",
      "fuzzy_match": false
    },
    "product_tags": [
      "general_technology",
      "medical"
    ],
    "published_at": "2026-09-30T12:43:21Z",
    "effective_date": "2026-09-30",
    "article_sentence": "As Simply Wall St reported on September 30, 2026, Gilead secured a USD 2.5 million federal grant with research partners for oral flavivirus treatments."
  }
}

curl https://signals.autobound.ai/v1/signals/a07027d8-638c-2569-2167-86ccbdfd29e4 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"gilead.com","limit":20}'